Live Breaking News & Updates on Sun Pharma Q3 Results
Stay updated with breaking news from Sun pharma q3 results. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The stock was trading with minor gains at the opening time and hit the day s high of Rs 1,430.45 on the NSE, up 0.84% over the Wednesday closing price. ....
Sun Pharmaceutical Industries reported a 17.4% YoY growth in net profit for Q4, beating estimates. Consolidated revenue grew 10% YoY. The company recommended an interim dividend payout. EBITDA rose 16% YoY and margins expanded. Raw material cost fell, but staff cost increased. India formulation sales and US formulation sales grew, while emerging markets formulation sales declined. ....
Sun Pharmaceutical Industries is set to release its Q3 results, with expected moderate earnings growth. Analysts will monitor factors including US business growth, Taro Pharmaceutical s performance, margin trajectory, planned product launches, and R&D investments. Estimated growth in net profit, revenue, and operating profit is also anticipated. The company is expected to see a rise in US revenue, driven by specialty sales. Growth in domestic formulations is projected, and R&D spend will be closely monitored. ....
Sun Pharmaceuticals and Maruti Suzuki India are among the companies declaring their Q3FY24 earnings. Maruti Suzuki India is expected to report healthy revenue growth, while Sun Pharmaceuticals may see moderate revenue growth. ....
Sun Pharma Q3 results: The company's consolidated profit after tax came at Rs 2,523.75 crore for the quarter ended December 31, 2023, as against Rs 2,166.01 crore in the same period last fiscal.